Back to Clinical Trials

Brief Title: Ask Questions (ASQ):Implementation of a Communication Intervention

Ask Questions (ASQ): Implementation of a Communication Intervention to Improve Patient-Oncologist Communication in the Outpatient Medical Oncology Setting

INTRODUCTION

  • Org Study ID: 2021-025
  • Secondary ID: N/A
  • NTC ID: NCT05025748
  • Sponsor: Barbara Ann Karmanos Cancer Institute

BRIEF SUMMARY

This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.

DETAILED DESCRIPTION

Patient-centered communication is critical to providing high-quality care. In patient-provider clinical interactions, providers are responsible for several aspects of patient-centered communication. However, to reach the goal of providing the best possible treatments, patients should also actively participate by asking questions and expressing their concerns. Question prompt lists, simple lists of questions provided to patients before clinic visits to help them prepare for the appointment, have been tested in several medical contexts and patient populations, including among an underserved, minority population in Detroit, and have been shown to contribute to improved outcomes related to better communication quality. Using a RE-AIM framework, this descriptive, mixed methods, single-arm intervention study assesses the implementation of an evidence-based communication intervention (question prompt list), the "ASQ brochure". The ASQ brochure is designed to improve patient-oncologist communication and other outcomes by improving patient self-efficacy for managing patient-physician interactions. Investigators will recruit 225 patients and implement the ASQ brochure at seven Karmanos Cancer Center network sites. Participants are newly diagnosed patients with (Stages I-IV) cancer for which systemic therapy is likely a recommended treatment.

  • Overall Status
    Recruiting
  • Start Date
    August 25, 2021
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Self-efficacy in managing patient-physician interactions

Primary Outcome 1 - Timeframe: Baseline (Time 1) to pre-clinic visit (TIme 2) post-clinic visit (TIme 3)

CONDITION

  • Stage II Breast Cancer
  • Stage III Breast Cancer
  • Stage IV Breast Cancer
  • Stage II Colorectal Cancer
  • Stage III Colorectal Cancer
  • Stage IV Colorectal Cancer
  • Stage II Lung Cancer
  • Stage III Lung Cancer
  • Stage IV Lung Cancer
  • Stage II Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer
  • Stage II Ovarian Cancer
  • Stage III Ovarian Cancer
  • Stage IV Ovarian Cancer
  • Stage II Cervical Cancer
  • Stage III Cervical Cancer
  • Stage II Bladder Cancer
  • Stage III Bladder Cancer
  • Stage IV Bladder Cancer
  • Stage II Kidney Cancer
  • Stage III Kidney Cancer
  • Stage IV Kidney Cancer

ELIGIBILITY

Inclusion Criteria:
Adults 18 years of age or older

- Have a first appointment to see a medical oncologist at a Karmanos Cancer Institute (KCC) site for medical/systemic treatment for a new, confirmed diagnosis of stages I-IV cancer

- Speak and read English well enough to be able to understand consent documents

- Given the diverse population seen at KCI, we will make attempts to recruit a representative sample. Our strategy will be simply to ask recruiters to make special attempts to recruit a representative sample. If that strategy fails after the first 10 patients we will build in requirements that at least 25% of the patients self-identify as non-White
Exclusion Criteria:
Not specified

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Susan Eggly, PhD

Role: Principal Investigator

Affiliation: Wayne State University

Overall Contact

Name: Susan Eggly, PhD

Phone: 313-576-8260

Email: egglys@karmanos.org, baidounf@karmanos.org

LOCATION

Facility Status Contact
Facility: Karmanos Cancer Institute at McLaren Bay Region
Bay City, Michigan 48706
United States
Status: Recruiting Contact: Contact
Susan Eggly, PhD
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Clarkston
Clarkston, Michigan 48346
United States
Status: Recruiting Contact: Contact
Susan Eggly, PhD
313-576-8260
Facility: Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Status: Recruiting Contact: Contact
Susan Eggly, Ph.D.
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Flint
Flint, Michigan 48532
United States
Status: Recruiting Contact: Principal Investigator
Susan Eggly, Ph.D.
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Macomb
Mount Clemens, Michigan 48043
United States
Status: Recruiting Contact: Sub-Investigator
Lauren Hamel, Ph.D.
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Central Michigan
Mount Pleasant, Michigan 48858
United States
Status: Recruiting Contact: Sub-Investigator
Seongho Kim, Ph.D
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Northern Michigan
Petoskey, Michigan 49770
United States
Status: Recruiting Contact: Sub-Investigator
Voncile Brown-Miller, Ph.D
313-576-8260
Facility: Karmanos Cancer Institute at McLaren Port Huron
Port Huron, Michigan 48060
United States
Status: Recruiting Contact: Contact
Susan Eggly, PhD
313-576-8260